🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

25 recruiting trials

for NSCLC Patients With Brain Metastasis

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site📍 Jerusalem Hadassah Medical Organization · Tests: Stereotactic surgery A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562Phase 115 sites📍 Scottsdale📍 Scottsdale📍 New Haven Cogent Biosciences, Inc. · Tests: CGT4255 Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis NCT06315010Phase 217 sites📍 Graz📍 Vienna📍 München MedSIR · Tests: Repotrectinib AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases NCT06604689n/a1 site📍 Shanghai Fudan University · Tests: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases NCT07304739Phase 23 sites📍 Cangzhou📍 Tianjin📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis NCT06501391Phase 21 site📍 Shanghai Fudan University · Tests: PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab NCT07619599Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomo… Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924Phase 1, Phase 249 sites📍 Gilbert📍 Los Angeles📍 Los Angeles Institut de Recherches Internationales Servier · Tests: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor NCT07755397Phase 16 sites📍 Surat📍 Bangalore📍 Mumbai Jubilant Therapeutics India Limited · Tests: JBI-778 A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases NCT06970639Phase 31 site📍 Guangdong Allist Pharmaceuticals, Inc. · Tests: Furmonertinib Mesilate Tablets, Carboplatin Injection, Cisplatin for injection, Pemetrexed Disodium for Injection, Osim… Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases NCT05064280Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Pembrolizumab, Lenvatinib The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases? NCT05378633NA1 site📍 Heidelberg University Hospital Heidelberg · Tests: SRS, Whole Brain Radiotherapy TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NCT05948813Phase 21 site📍 Beijing TYK Medicines, Inc · Tests: TY-9591, Osimertinib A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain NCT06741085Phase 28 sites📍 Miami📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: osimertinib, stereotactic radiosurgery (SRS) Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements NCT05987644Phase 1, Phase 23 sites📍 Stanford📍 Aurora📍 Columbus Joshua Palmer · Tests: Alectinib, Stereotactic Radiosurgery SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET) NCT05689619NA6 sites📍 Genova📍 Messina📍 Rome A.O.U. Città della Salute e della Scienza · Tests: Silibinin, Placebo Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer NCT02448992Phase 2, Phase 31 site📍 Taoyuan Chang Gung Memorial Hospital · Tests: hippocampal-sparing WBRT Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. NCT06238882NA1 site📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Nitroglycerin Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases NCT07130786Phase 21 site📍 Boston Ayal A. Aizer, MD · Tests: Levetiracetam (Keppra) Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer NCT05864794NA3 sites📍 Groningen📍 Maastricht📍 Scheemda University Medical Center Groningen · Tests: MRI Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases NCT06248606Phase 23 sites📍 Columbus📍 Charlottesville📍 Richmond Ryan Gentzler, MD · Tests: Adagrasib, Stereotactic Radiosurgery Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379Phase 1, Phase 28 sites📍 Beverly Hills📍 Glendale📍 Los Angeles Neonc Technologies, Inc. · Tests: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC NCT07206498Phase 1, Phase 21 site📍 Shanghai Wayshine Biopharm, Inc. · Tests: Osimertinib (Tagrisso®), WSD0922-FU Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer NCT05522660Phase 315 sites📍 Naples📍 Padova📍 Perugia ETOP IBCSG Partners Foundation · Tests: Stereotactic radiosurgery, Immune checkpoint inhibitor Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases NCT06401824Phase 23 sites📍 Amsterdam📍 Groningen📍 Maastricht Maastricht University Medical Center · Tests: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy